Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
71 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pulmonary Hypertension - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pulmonary Hypertension - Pipeline Review, H2 2014', provides an overview of the Pulmonary Hypertension's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Pulmonary Hypertension Overview 8 Therapeutics Development 9 Pipeline Products for Pulmonary Hypertension - Overview 9 Pipeline Products for Pulmonary Hypertension - Comparative Analysis 10 Pulmonary Hypertension - Therapeutics under Development by Companies 11 Pulmonary Hypertension - Therapeutics under Investigation by Universities/Institutes 13 Pulmonary Hypertension - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Pulmonary Hypertension - Products under Development by Companies 17 Pulmonary Hypertension - Products under Investigation by Universities/Institutes 18 Pulmonary Hypertension - Companies Involved in Therapeutics Development 19 Sanofi 19 Vectura Group plc 20 Bayer AG 21 Ikaria Inc. 22 Proreo Pharma AG 23 Vicore Pharma AB 24 Biolab Sanus Farmaceutica Ltda. 25 Hanmi Pharmaceuticals, Co. Ltd. 26 Pulmonary Hypertension - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 Nepolong - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 VR-876 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 IK-3001 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 sildenafil citrate IMD - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 IK-7002 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 riociguat - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 SAR-407899 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 SAR-164653 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 C-21 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Drug for Pulmonary Hypertension - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 R-100 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 BL-214 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules for Inflammatory and Metabolic Diseases - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Drug for Pulmonary Hypertension - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecules to Inhibit Metap2 for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BAY sGCact - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Pulmonary Hypertension - Recent Pipeline Updates 56 Pulmonary Hypertension - Dormant Projects 64 Pulmonary Hypertension - Product Development Milestones 65 Featured News & Press Releases 65 Jun 03, 2014: Bayer to Evaluate Riociguat in New Indication 65 Mar 31, 2014: Bayer's Adempas Approved for the Treatment of Two Life-Threatening Forms of Pulmonary Hypertension in the EU 65 Jan 24, 2014: Bayer's Riociguat Recommended for Approval in the EU in Two Forms of Pulmonary Hypertension 66 Jul 24, 2013: New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer's Riociguat 68 Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 71 Disclaimer 71
List of Tables Number of Products under Development for Pulmonary Hypertension, H2 2014 9 Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Pulmonary Hypertension - Pipeline by Sanofi, H2 2014 19 Pulmonary Hypertension - Pipeline by Vectura Group plc, H2 2014 20 Pulmonary Hypertension - Pipeline by Bayer AG, H2 2014 21 Pulmonary Hypertension - Pipeline by Ikaria Inc., H2 2014 22 Pulmonary Hypertension - Pipeline by Proreo Pharma AG, H2 2014 23 Pulmonary Hypertension - Pipeline by Vicore Pharma AB, H2 2014 24 Pulmonary Hypertension - Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2014 25 Pulmonary Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Pulmonary Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 56 Pulmonary Hypertension - Dormant Projects, H2 2014 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.